Medication info
Zadimet Tablet 5/1000 mg (Empagliflozin, Metformin Hydrochloride)

Zadimet Tablet 5/1000 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
JW Pharmaceutical Corp.
Appearance
Yellow, biconvex, oval-shaped film-coated tablet with a brown tint
Packaging
10 tablets/box [10 tablets/PTP×1], 60 tablets/box [10 tablets/PTP×6], 60 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202201743 · Approved 2022.04.29 · Insurance code 644915070

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from concomitant therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their current doses of empagliflozin and metformin. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose is missed, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is required in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Careful Administration, subsection 1)). If renal function declines to a CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, subsection 2)). Older adults In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into account.

Ingredients

Manufacturer
JW Pharmaceutical Corp.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood glucose control
  • type 2 diabetes
  • cardiovascular diseases
View approved original text

This medication works in combination with empagliflozin and metformin to improve blood glucose control in adult patients with type 2 diabetes, alongside dietary management and exercise therapy. It is especially suitable for patients whose blood glucose is not well controlled, and should be administered under the guidance of a specialist in patients with cardiovascular disease. This can effectively improve blood glucose management.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from concomitant therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their current doses of empagliflozin and metformin. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose is missed, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is required in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Careful Administration, subsection 1)). If renal function declines to a CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, subsection 2)). Older adults In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into account.

Precautions

This medication is used for the treatment of type 2 diabetes and acts to lower blood glucose through its two components. It can cause a rare side effect called severe lactic acidosis, so it should not be used in cases of impaired kidney function, severe infections, dehydration, or heart failure. Additionally, caution is needed when taken with insulin or sulfonylureas as there is an increased risk of hypoglycemia. Patients with moderate or severe impairment of kidney function should not take this medication, and regular kidney function tests should be performed before and during treatment. In the case of acute illnesses, upcoming surgery, or severe infections or dehydration, the use of this medication should be temporarily discontinued. Pregnant or breastfeeding women should not use this medication, and especially women with potential for pregnancy should consult a physician before taking it. This medication may increase the risk of urinary tract infections and genital infections, so immediate medical attention is needed if symptoms of infection appear. During usage, it is important to watch for signs of hypoglycemia, particularly when taken with insulin or other glucose-lowering agents. Vitamin B12 deficiency may occur, so patients using this medication for long periods should regularly check their vitamin B12 levels. Alcohol consumption can increase the risk of lactic acidosis, so excessive drinking should be avoided while taking this medication. This medication can lead to fluid loss and a decrease in blood pressure, so elderly patients or those at risk of fluid loss should use it with caution. Throughout treatment, blood glucose control, kidney function, and infection status should be closely monitored, and immediate consultation with healthcare providers is necessary if any abnormal symptoms arise. This medication has not been established as safe and effective for children, therefore it should not be used in individuals under 18 years of age. In the event of an overdose, serious side effects such as lactic acidosis may occur, so adherence to the prescribed dosage is crucial, and immediate hospital visit is required if side effects arise. This medication should be stored in its original container, out of reach of children.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
Show 181 more
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • urticaria
  • erythema nodosum
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
  • gangrene of the perineum
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • lower gastrointestinal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • headache
  • sensory impairment
  • orthostatic dizziness
  • dizziness
  • amnesia
  • carotid stenosis
  • diabetic neuropathy
  • facial paralysis
  • neuralgia
  • Parkinson's disease
  • polyneuropathy
  • drowsiness
  • CNS-origin vertigo
  • fatigue
  • peripheral edema
  • facial edema
  • peripheral swelling
  • fever
  • facial swelling
  • chills
  • abnormal sensation
  • swelling
  • pain
  • pain at puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight gain
  • abnormal electrocardiogram
  • decreased hemoglobin
  • increased hemoglobin
  • positive Helicobacter test
  • positive urine red blood cells
  • urinary stones
  • hematuria
  • renal mass
  • urinary retention
  • abnormal urine
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • cervical inflammation
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge
  • hypoglycemia
  • decreased appetite
  • obesity
  • acanthosis nigricans
  • diabetes mellitus
  • hyperlipidemia
  • hyponatremia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal abrasion
  • macular fibrosis
  • eye discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal embolism
  • retinal vein occlusion
  • rhegmatogenous retinal detachment
  • eyelid edema
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • productive cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular disease
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • orthostatic vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is also recommended to avoid extremely hot or cold places, and to keep it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Yellow, biconvex, oval-shaped film-coated tablet with a brown tint

Package unit

10 tablets/box [10 tablets/PTP×1], 60 tablets/box [10 tablets/PTP×6], 60 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.